Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another

Zinger Key Points
  • Bank of America recommends Merck over Pfizer in 2023.
  • Merck's "consistent revenue upside" generates value for investors, one analyst says.

The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be a volatile 2023.

The Analyst: Bank of America analyst Geoff Meacham upgraded Merck & Co Inc MRK from Neutral to Buy and raised his price target from $110 to $130. Meacham also downgraded Pfizer Inc. PFE from Buy to Neutral and reiterated his $60 price target.

Related Link: Stock Strategist Lists 5 Reasons To 'Stick With Value' In 2023

The Thesis: In the Merck upgrade note, Meacham said the company demonstrated strong commercial execution in a difficult macroeconomic environment and continued to generate impressive revenue growth.

"Indeed, at a time where the macro backdrop could remain uncertain throughout most of 2023, Merck's consistent revenue upside (1Q22: +$1.3B; 2Q22: +$751M; 3Q22: +$490M) should be highly valued, in our view," Meacham said.

At the same time, Meacham warned Keytruda concentration remained a risk for investors given the drug was on track to account for greater than 45% of Merck's total revenue by 2025.

Related Link: 'Sell The Darlings, Own The Dogs': Why It May Soon Be Time To Buy Tesla, Meta And Other Worst-Performing Stocks Of 2022

Meacham said Pfizer had now become a "show-me" stock with a lot to prove in a post-COVID-19 pandemic world. Pfizer is approaching loss of exclusivity on drugs representing about $17 billion in sales from 2025 through 2030. Pfizer has guided for drug launches worth a collective $20 billion in new revenue by 2030, but Meacham said additional upside for the stock would likely be driven largely by product launches that occur in 2024 and beyond.

Benzinga's Take: Pfizer and Merck are two of the biggest and best blue chip investments in the defensive health care sector, and both companies will likely make excellent long-term investments at current levels. However, Merck may pay off more for investors in 2023 given Pfizer's lack of meaningful near-term catalysts ahead.

Photo: Gorodenkoff via Shutterstock

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorLarge CapNewsUpgradesDowngradesHealth CarePrice TargetTop StoriesAnalyst RatingsTrading IdeasGeneralBank of AmericaGeoff Meachampharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!